Maynard Um
-
-
-
-
-
-
-
BridgeBio Pharma (BBIO) files mixed shelf
-
-
-
-
-
-
-
Raymond James on BridgeBio Pharma (BBIO): 'We expect continued strong commercial momentum for Attruby'
-
-
-
-
-
-
-
Barclays: 'We think dropping the question of '441 validity from the case is a major development'
-
-
-
-
-
-
-
RBC Capital Starts BridgeBio Pharma (BBIO) at Outperform
-
-
-
-
-
-
-
BridgeBio Pharma (BBIO) PT Raised to $106 at Mizuho
-
-
-
-
-
-
-
TD Cowen comments on BridgeBio Pharma following positive infigratinib data
-
-
-
-
-
-
-
Here's the list of top biotech stocks to own for 2026
-
397,130 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

